Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib

Yurina Saito; Tsuyoshi Takahashi; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki

Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib

Yurina Saito, Tsuyoshi Takahashi, Koji Tanaka, Yasuhiro Miyazaki, Tomoki Makino, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori, Yuichiro Doki

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Imatinib mesylate has dramatically improved the survival with unresectable or metastatic GIST, whereas many patients subsequently develop imatinib resistance. Followed by sunitinib, regorafenib has been approved since 2013 in Japan. We aimed to assess efficacy and safety of regorafenib in GIST patients in clinical setting. The study was conducted between August 2013 and April 2016, among 11 patients with GIST treated by regorafenib. The median treatment duration was 8.4 months. The median progression-free survival (PFS) was 7.4 months. Nine patients experienced at least one Grade 3 or 4 toxicity from regorafenib. The most common Grade 3 toxicity was hand-and-foot skin reactions (4 of 11; 36.4%), followed by hypertension (3 of 11; 27.3%). Dose reduction was required in 8 patients. Although dose modifications due to toxicities were very common, some patients achieved long PFS with regorafenib treatment.

Original language	English
Pages (from-to)	121-123
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	45
Issue number	1
Publication status	Published - Jan 2018
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib'. Together they form a unique fingerprint.

Cite this

Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib. / Saito, Yurina; Takahashi, Tsuyoshi; Tanaka, Koji; Miyazaki, Yasuhiro; Makino, Tomoki; Kurokawa, Yukinori; Yamasaki, Makoto; Nakajima, Kiyokazu; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 45, No. 1, 01.2018, p. 121-123.

Research output: Contribution to journal › Review article › peer-review

Saito, Yurina ; Takahashi, Tsuyoshi ; Tanaka, Koji ; Miyazaki, Yasuhiro ; Makino, Tomoki ; Kurokawa, Yukinori ; Yamasaki, Makoto ; Nakajima, Kiyokazu ; Takiguchi, Shuji ; Mori, Masaki ; Doki, Yuichiro. / Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib. In: Japanese Journal of Cancer and Chemotherapy. 2018 ; Vol. 45, No. 1. pp. 121-123.

@article{bf77460cfbb64d2489b9206ed2fd5327,

title = "Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib",

abstract = "Imatinib mesylate has dramatically improved the survival with unresectable or metastatic GIST, whereas many patients subsequently develop imatinib resistance. Followed by sunitinib, regorafenib has been approved since 2013 in Japan. We aimed to assess efficacy and safety of regorafenib in GIST patients in clinical setting. The study was conducted between August 2013 and April 2016, among 11 patients with GIST treated by regorafenib. The median treatment duration was 8.4 months. The median progression-free survival (PFS) was 7.4 months. Nine patients experienced at least one Grade 3 or 4 toxicity from regorafenib. The most common Grade 3 toxicity was hand-and-foot skin reactions (4 of 11; 36.4%), followed by hypertension (3 of 11; 27.3%). Dose reduction was required in 8 patients. Although dose modifications due to toxicities were very common, some patients achieved long PFS with regorafenib treatment.",

author = "Yurina Saito and Tsuyoshi Takahashi and Koji Tanaka and Yasuhiro Miyazaki and Tomoki Makino and Yukinori Kurokawa and Makoto Yamasaki and Kiyokazu Nakajima and Shuji Takiguchi and Masaki Mori and Yuichiro Doki",

year = "2018",

month = jan,

language = "English",

volume = "45",

pages = "121--123",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "1",

}

TY - JOUR

T1 - Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib

AU - Saito, Yurina

AU - Takahashi, Tsuyoshi

AU - Tanaka, Koji

AU - Miyazaki, Yasuhiro

AU - Makino, Tomoki

AU - Kurokawa, Yukinori

AU - Yamasaki, Makoto

AU - Nakajima, Kiyokazu

AU - Takiguchi, Shuji

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2018/1

Y1 - 2018/1

N2 - Imatinib mesylate has dramatically improved the survival with unresectable or metastatic GIST, whereas many patients subsequently develop imatinib resistance. Followed by sunitinib, regorafenib has been approved since 2013 in Japan. We aimed to assess efficacy and safety of regorafenib in GIST patients in clinical setting. The study was conducted between August 2013 and April 2016, among 11 patients with GIST treated by regorafenib. The median treatment duration was 8.4 months. The median progression-free survival (PFS) was 7.4 months. Nine patients experienced at least one Grade 3 or 4 toxicity from regorafenib. The most common Grade 3 toxicity was hand-and-foot skin reactions (4 of 11; 36.4%), followed by hypertension (3 of 11; 27.3%). Dose reduction was required in 8 patients. Although dose modifications due to toxicities were very common, some patients achieved long PFS with regorafenib treatment.

AB - Imatinib mesylate has dramatically improved the survival with unresectable or metastatic GIST, whereas many patients subsequently develop imatinib resistance. Followed by sunitinib, regorafenib has been approved since 2013 in Japan. We aimed to assess efficacy and safety of regorafenib in GIST patients in clinical setting. The study was conducted between August 2013 and April 2016, among 11 patients with GIST treated by regorafenib. The median treatment duration was 8.4 months. The median progression-free survival (PFS) was 7.4 months. Nine patients experienced at least one Grade 3 or 4 toxicity from regorafenib. The most common Grade 3 toxicity was hand-and-foot skin reactions (4 of 11; 36.4%), followed by hypertension (3 of 11; 27.3%). Dose reduction was required in 8 patients. Although dose modifications due to toxicities were very common, some patients achieved long PFS with regorafenib treatment.

UR - http://www.scopus.com/inward/record.url?scp=85043442700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043442700&partnerID=8YFLogxK

M3 - Review article

C2 - 29362328

AN - SCOPUS:85043442700

VL - 45

SP - 121

EP - 123

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 1

ER -

Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Cite this